Drugs / Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
also known as
Menactra
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02842853 Comparator | Jul 2016 → Feb 2017 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02842853 ↗ |
| Known as | Menactra | “Menactra®” NCT02842853 ↗ |
| Modality | Vaccine | “Meningococcal Conjugate Vaccine” NCT02842853 ↗ |
| Route | Intramuscular | “0.5 mL, Intramuscular” NCT02842853 ↗ |